COLLAGEN XIII-DEPENDENT MYASTHENIAS – MECHANISMS AND THERAPEUTIC PROSPECTS
Description of the granted funding
We address the roles and molecular interactions of collagen XIII (ColXIII) in the neuromuscular junction (NMJ). We have shown that ColXIII is an essential NMJ component and others have recently shown that mutations in the human gene cause congenital myasthenic syndrome type 19 (CMS19). Using mouse and cell culture models we will identify the network of molecules and the events whereby ColXIII operates in the normal NMJ and the developmental events that lead to CMS19. We will also determine the occurrence of anti-ColXIII autoimmuneantibodies in patients with acquired generalized and ocular myasthenia gravis and assess their effects on the NMJ. The research is performed at the Faculty of Biochemistry and Molecular Medicine, University of Oulu. The studies provide unique opportunities to enhance the understanding of critical motor synapse molecules and facilitate personalized therapies in genetic and acquired myasthenia. See (https://www.oulu.fi/university/researcher/taina-pihlajaniemi).
Show moreStarting year
2021
End year
2025
Granted funding
Other information
Funding decision number
341776
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
genes, genetics